Viewing Study NCT05091567


Ignite Creation Date: 2025-12-25 @ 12:31 AM
Ignite Modification Date: 2025-12-30 @ 7:11 AM
Study NCT ID: NCT05091567
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-10-22
First Post: 2021-10-12
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
Sponsor: Hoffmann-La Roche
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module